Pharma deal analysis divides US FTC
The US Federal Trade Commission has approved Bristol-Myers Squibb’s acquisition of Celgene on a party-line vote, but both Democratic commissioners called for the agency to look more broadly at consolidation in the pharmaceutical industry.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10